Liquidia - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsLiquidia

Liquidia(LQDA)

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

No data

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

wounds and injuries

,

renal insufficiency

,

diabetes mellitus

,

type 1 diabetes mellitus

,

hepatic insufficiency

,

healthy volunteers/patients

,

diffuse scleroderma

,

congenital heart defects

,

,

,

reperfusion injury

,

,

persistent fetal circulation syndrome

,

cardiovascular diseases

,

,

delayed graft function

,

,

,

,

,

respiratory distress syndrome

,

acute lung injury

,

newborn respiratory distress syndrome

,

,

localized scleroderma

,

,

hypertriglyceridemia

,

,

interstitial lung diseases

,

pulmonary fibrosis

,

chronic obstructive pulmonary disease

,

respiratory aspiration

,

idiopathic pulmonary fibrosis

,

,

,

vascular diseases

,

obstructive lung diseases

,

chronic limb-threatening ischemia

,

,

,

peripheral arterial disease

,

peripheral vascular diseases

,

sickle cell anemia

,

liver transplantation

,

,

pulmonary arterial hypertension

,

pulmonary hypertension

,

familial primary pulmonary hypertension

,

,

systemic scleroderma

,

raynaud disease

,

,

connective tissue diseases

,

lung transplantation

,

univentricular heart

,

chronic kidney failure

,

kidney diseases

,

,

type 2 diabetes mellitus

human influenza

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use